PT  - JOURNAL ARTICLE
AU  - S Aulmann
AU  - N Adler
AU  - J Rom
AU  - B Helmchen
AU  - P Schirmacher
AU  - H P Sinn
TI  - c-<em>myc</em> Amplifications in primary breast carcinomas and their local recurrences
AID  - 10.1136/jcp.2005.029264
DP  - 2006 Apr 01
TA  - Journal of Clinical Pathology
PG  - 424--4248
VI  - 59
IP  - 4
4099  - http://jcp.bmj.com/content/59/4/424.short
4100  - http://jcp.bmj.com/content/59/4/424.full
SO  - J Clin Pathol2006 Apr 01; 59
AB  - Objective: To evaluate the role of c-myc oncogene amplifications in the progression of invasive breast carcinomas. Methods: c-myc gene copy number was evaluated in a series of 49 primary breast carcinomas and the corresponding local recurrences using fluorescence in situ hybridisation. Results: 11 of the primary carcinomas (22%) harboured c-myc amplifications; these tumours typically were hormone receptor negative and occurred in younger patients (43 v 53 years). At the time of relapse, six additional tumours had acquired a c-myc amplification. The mean recurrence-free survival was 24 months; c-myc amplified tumours relapsed significantly earlier than carcinomas without amplification (18 v 27 months). Univariate analysis showed a worse overall survival in these patients. Conclusions: While c-myc amplifications can be observed in early stage breast cancer, especially in younger patients, they often occur later in tumour development and appear to be associated with disease progression.